- Activity pressure is constructive, supporting the smart-money activity read.
ALGN
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
Align Technology Inc · Healthcare · Medical Instruments & Supplies
Latest close
173.7 USD
2.7%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -0.9% below the Trend Line and sits at 65.9% of its 52-week range. The latest completed week returned 2.7%, after a -3.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is bullish with 38/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal.
Setup score
40
out of 100
Latest Close
173.7 USD
7 Aug 2026
1W Return
2.7%
latest completed week
4W Return
-3.2%
short-term follow-through
12W Return
10.4%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.7%
Latest completed week; four-week move -3.2%.
Indicator stack
26/21
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bullish
38/100 conviction; expected move 3.4%.
News sentiment
57/100
14 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -0.9% below the Trend Line and sits at 65.9% of its 52-week range. The latest completed week returned 2.7%, after a -3.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.5512-week average 0.47
12-week confirmation
Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.55Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -3.2% over four weeks, 10.4% over 12 weeks, and 24.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.45Latest activity-pressure read.
Pressure change-267.7%Four-week change in activity pressure.
Leadership-5.89Latest relative-leadership reading.
RS change-27.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 97%
Model confidence 97%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength27/100Blend of value, momentum, and quality. Underlying universe rank 74; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality100/100Profitability and accounting quality. Underlying universe rank 1; rank 1 is best.
Momentum34/100Medium-term price momentum. Underlying universe rank 67; rank 1 is best.
Growth4/100Revenue and earnings growth. Underlying universe rank 97; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework53/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 29.8x Price divided by trailing earnings.
- Price / sales
- 3.0x Market value relative to trailing revenue.
- EV / EBITDA
- 15.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 7.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 66.5% Gross profit retained from each unit of revenue.
- Operating margin
- 15.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 23.0% Free cash flow generated from revenue.
- Return on invested capital
- 14058.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 4.4% Latest one-year revenue growth.
- EPS growth
- -5.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 13.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 2.0% Net share repurchases relative to market value.
- Shareholder yield
- 2.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
ALGN shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.25, expected move of 3.4%, and Sharemaestro trend signal inactive.
Conviction38/100
Expected move3.4%
Put/call volume0.25
Insider activity13 / 7
13 acquisitions and 7 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment57/100
Weighted news tone is neutral across 14 relevant articles.
5 positive · 7 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move3.4%Nearest-chain priced movement where available.
52-week drawdown-13.4%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+9.8%Week of 17 Apr.
Worst week-8.5%Week of 6 Mar.
Latest week+2.7%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks0
Modest losses6
Sharp losses7
Recent vol4.2%13-week weekly-return volatility.
Base vol4.8%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew4.3% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank77 / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Medical Instruments & Supplies
4-week rank34 / 50
Group average4.5%
Trend breadth42.0%
Trend42.0%active weekly trend signals
MD70.0%positive activity pressure
RS32.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape37/100
Trend, activity pressure, participation, and risk combine to a 37/100 tape read.
Indicator analysis43/100Latest 12-week confirmation: trend 9/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.55; No reversal markers Factors43/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 23; Small Cap Core rank 88 SVQF53/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 335.0 of 718 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options44/100ALGN shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.25, expected move of 3.4%, and Sharemaestro trend signal inactive.
Bullish · Call-side pressure · Expected move 3.4% Sentiment57/100Weighted news tone is neutral across 14 relevant articles.
Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median? Insiders13 / 713 acquisitions and 7 disposals in the latest 180-day insider tape.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 173.7 USD | 2.7% | 175.2 USD | 212.5 USD | -0.45 | -5.89 | 4.7M | Off |
| 31 Jul 2026 | 169.2 USD | 1.3% | 175.2 USD | 213.7 USD | -0.35 | -3.69 | 6.7M | Off |
| 24 Jul 2026 | 167.0 USD | -5.5% | 174.7 USD | 214.9 USD | -0.16 | -4.40 | 3.9M | On |
| 17 Jul 2026 | 176.8 USD | -1.5% | 174.4 USD | 216.3 USD | 0.15 | -1.33 | 3.7M | On |
| 10 Jul 2026 | 179.4 USD | -2.7% | 173.8 USD | 217.3 USD | 0.27 | -4.62 | 4.8M | On |
| 3 Jul 2026 | 184.5 USD | 3.4% | 173.3 USD | 218.5 USD | 0.17 | -1.02 | 5.2M | On |
| 26 Jun 2026 | 178.4 USD | -2.0% | 172.4 USD | 219.4 USD | -0.20 | -4.14 | 6.4M | On |
| 19 Jun 2026 | 182.1 USD | 4.1% | 171.4 USD | 220.6 USD | -0.44 | -7.21 | 4.5M | On |
| 12 Jun 2026 | 174.8 USD | 4.2% | 170.1 USD | 221.5 USD | -0.70 | -9.18 | 4.8M | On |
| 5 Jun 2026 | 167.7 USD | -4.1% | 168.8 USD | 222.5 USD | -0.94 | -11.47 | 4.3M | Off |
| 29 May 2026 | 174.9 USD | 6.9% | 167.7 USD | 223.4 USD | -0.87 | -12.47 | 5.2M | On |
| 22 May 2026 | 163.6 USD | 4.0% | 166.5 USD | 224.2 USD | -0.72 | -16.45 | 5.9M | On |
| 15 May 2026 | 157.2 USD | -6.8% | 165.5 USD | 225.0 USD | -0.47 | -19.34 | 4.0M | On |
| 8 May 2026 | 168.8 USD | -5.7% | 164.6 USD | 225.8 USD | -0.16 | -14.54 | 3.8M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.